Lithium-induced  ||| S:0 E:16 ||| JJ
nephrogenic  ||| S:16 E:28 ||| JJ
diabetes  ||| S:28 E:37 ||| NN
insipidus ||| S:37 E:46 ||| NNS
:  ||| S:46 E:48 ||| :
new  ||| S:48 E:52 ||| JJ
clinical  ||| S:52 E:61 ||| JJ
and  ||| S:61 E:65 ||| CC
experimental  ||| S:65 E:78 ||| JJ
findings  ||| S:78 E:87 ||| NNS
Lithium  ||| S:87 E:95 ||| NNP
( ||| S:95 E:96 ||| -LRB-
Li+ ||| S:96 E:99 ||| NNP
)  ||| S:99 E:101 ||| -RRB-
salts  ||| S:101 E:107 ||| NNS
are  ||| S:107 E:111 ||| VBP
widely  ||| S:111 E:118 ||| RB
used  ||| S:118 E:123 ||| VBN
to  ||| S:123 E:126 ||| TO
treat  ||| S:126 E:132 ||| VB
bipolar  ||| S:132 E:140 ||| JJ
mood  ||| S:140 E:145 ||| NN
disorders ||| S:145 E:154 ||| NNS
.  ||| S:154 E:156 ||| .
Recent  ||| S:156 E:163 ||| JJ
trials  ||| S:163 E:170 ||| NNS
suggest  ||| S:170 E:178 ||| VBP
a  ||| S:178 E:180 ||| DT
potential  ||| S:180 E:190 ||| JJ
efficacy  ||| S:190 E:199 ||| NNS
also  ||| S:199 E:204 ||| RB
in  ||| S:204 E:207 ||| IN
the  ||| S:207 E:211 ||| DT
treatment  ||| S:211 E:221 ||| NN
of  ||| S:221 E:224 ||| IN
amyotrophic  ||| S:224 E:236 ||| JJ
lateral  ||| S:236 E:244 ||| JJ
sclerosis  ||| S:244 E:254 ||| NN
and  ||| S:254 E:258 ||| CC
Alzheimer ||| S:258 E:267 ||| NNP
's  ||| S:267 E:270 ||| POS
disease ||| S:270 E:277 ||| NN
.  ||| S:277 E:279 ||| .
Li+  ||| S:279 E:283 ||| NNP
is  ||| S:283 E:286 ||| VBZ
freely  ||| S:286 E:293 ||| RB
filtered  ||| S:293 E:302 ||| VBN
by  ||| S:302 E:305 ||| IN
the  ||| S:305 E:309 ||| DT
glomerulus  ||| S:309 E:320 ||| NN
and  ||| S:320 E:324 ||| CC
mainly  ||| S:324 E:331 ||| RB
reabsorbed  ||| S:331 E:342 ||| VBN
in  ||| S:342 E:345 ||| IN
the  ||| S:345 E:349 ||| DT
proximal  ||| S:349 E:358 ||| JJ
convoluted  ||| S:358 E:369 ||| JJ
tubule ||| S:369 E:375 ||| NN
.  ||| S:375 E:377 ||| .
Reabsorption  ||| S:377 E:390 ||| NNP
in  ||| S:390 E:393 ||| IN
the  ||| S:393 E:397 ||| DT
distal  ||| S:397 E:404 ||| JJ
nephron  ||| S:404 E:412 ||| NN
becomes  ||| S:412 E:420 ||| VBZ
significant  ||| S:420 E:432 ||| JJ
under  ||| S:432 E:438 ||| IN
sodium-restricted  ||| S:438 E:456 ||| JJ
conditions ||| S:456 E:466 ||| NNS
.  ||| S:466 E:468 ||| .
Nevertheless ||| S:468 E:480 ||| RB
,  ||| S:480 E:482 ||| ,
the  ||| S:482 E:486 ||| DT
distal  ||| S:486 E:493 ||| JJ
nephron  ||| S:493 E:501 ||| NN
is  ||| S:501 E:504 ||| VBZ
greatly  ||| S:504 E:512 ||| RB
affected  ||| S:512 E:521 ||| VBN
by  ||| S:521 E:524 ||| IN
Li+  ||| S:524 E:528 ||| NNP
even  ||| S:528 E:533 ||| RB
under  ||| S:533 E:539 ||| IN
normal  ||| S:539 E:546 ||| JJ
sodium  ||| S:546 E:553 ||| JJ
intake ||| S:553 E:559 ||| NN
.  ||| S:559 E:561 ||| .
Polyuria ||| S:561 E:569 ||| NNP
,  ||| S:569 E:571 ||| ,
renal  ||| S:571 E:577 ||| JJ
tubular  ||| S:577 E:585 ||| JJ
acidosis  ||| S:585 E:594 ||| NN
and  ||| S:594 E:598 ||| CC
finally  ||| S:598 E:606 ||| RB
chronic  ||| S:606 E:614 ||| JJ
renal  ||| S:614 E:620 ||| JJ
failure  ||| S:620 E:628 ||| NN
are  ||| S:628 E:632 ||| VBP
the  ||| S:632 E:636 ||| DT
most  ||| S:636 E:641 ||| RBS
frequent  ||| S:641 E:650 ||| JJ
adverse  ||| S:650 E:658 ||| JJ
effects ||| S:658 E:665 ||| NNS
.  ||| S:665 E:667 ||| .
The  ||| S:667 E:671 ||| DT
occurrence  ||| S:671 E:682 ||| NN
of  ||| S:682 E:685 ||| IN
an  ||| S:685 E:688 ||| DT
overt  ||| S:688 E:694 ||| FW
nephrogenic  ||| S:694 E:706 ||| FW
diabetes  ||| S:706 E:715 ||| FW
insipidus  ||| S:715 E:725 ||| FW
( ||| S:725 E:726 ||| -LRB-
NDI ||| S:726 E:729 ||| NNP
)  ||| S:729 E:731 ||| -RRB-
limits  ||| S:731 E:738 ||| VBZ
Li+  ||| S:738 E:742 ||| CD
usage  ||| S:742 E:748 ||| NN
and  ||| S:748 E:752 ||| CC
imposes  ||| S:752 E:760 ||| JJ
suspension ||| S:760 E:770 ||| NN
.  ||| S:770 E:772 ||| .
The  ||| S:772 E:776 ||| DT
molecular  ||| S:776 E:786 ||| JJ
mechanisms  ||| S:786 E:797 ||| NNS
of  ||| S:797 E:800 ||| IN
Li+-related  ||| S:800 E:812 ||| CD
urinary  ||| S:812 E:820 ||| JJ
concentration  ||| S:820 E:834 ||| NN
defect  ||| S:834 E:841 ||| NNS
involve  ||| S:841 E:849 ||| VBP
a  ||| S:849 E:851 ||| DT
dysregulation  ||| S:851 E:865 ||| NN
of  ||| S:865 E:868 ||| IN
the  ||| S:868 E:872 ||| DT
aquaporin  ||| S:872 E:882 ||| JJ
system  ||| S:882 E:889 ||| NN
in  ||| S:889 E:892 ||| IN
principal  ||| S:892 E:902 ||| JJ
cells  ||| S:902 E:908 ||| NNS
of  ||| S:908 E:911 ||| IN
the  ||| S:911 E:915 ||| DT
collecting  ||| S:915 E:926 ||| JJ
duct ||| S:926 E:930 ||| NN
.  ||| S:930 E:932 ||| .
ENaC  ||| S:932 E:937 ||| NNP
is  ||| S:937 E:940 ||| VBZ
crucial  ||| S:940 E:948 ||| JJ
as  ||| S:948 E:951 ||| IN
the  ||| S:951 E:955 ||| DT
entry  ||| S:955 E:961 ||| NN
route  ||| S:961 E:967 ||| NN
for  ||| S:967 E:971 ||| IN
intracellular  ||| S:971 E:985 ||| CD
Li+  ||| S:985 E:989 ||| CD
accumulation ||| S:989 E:1001 ||| NN
.  ||| S:1001 E:1003 ||| .
The  ||| S:1003 E:1007 ||| DT
basolateral  ||| S:1007 E:1019 ||| JJ
exit  ||| S:1019 E:1024 ||| NN
route  ||| S:1024 E:1030 ||| NN
is  ||| S:1030 E:1033 ||| VBZ
not  ||| S:1033 E:1037 ||| RB
clearly  ||| S:1037 E:1045 ||| RB
identified ||| S:1045 E:1055 ||| VBN
,  ||| S:1055 E:1057 ||| ,
but  ||| S:1057 E:1061 ||| CC
some  ||| S:1061 E:1066 ||| DT
evidence  ||| S:1066 E:1075 ||| NN
suggests  ||| S:1075 E:1084 ||| VBZ
Na+ ||| S:1084 E:1087 ||| CD
/ ||| S:1087 E:1088 ||| CD
H+  ||| S:1088 E:1091 ||| CD
exchanger  ||| S:1091 E:1101 ||| CD
1  ||| S:1101 E:1103 ||| CD
( ||| S:1103 E:1104 ||| -LRB-
NHE1 ||| S:1104 E:1108 ||| NNP
)  ||| S:1108 E:1110 ||| -RRB-
as  ||| S:1110 E:1113 ||| IN
a  ||| S:1113 E:1115 ||| DT
potential  ||| S:1115 E:1125 ||| JJ
candidate ||| S:1125 E:1134 ||| NN
.  ||| S:1134 E:1136 ||| .
Li+  ||| S:1136 E:1140 ||| NNP
promotes  ||| S:1140 E:1149 ||| VBZ
polyuria  ||| S:1149 E:1158 ||| VBN
mainly  ||| S:1158 E:1165 ||| RB
counteracting  ||| S:1165 E:1179 ||| VB
the  ||| S:1179 E:1183 ||| DT
intracellular  ||| S:1183 E:1197 ||| JJ
vasopressin  ||| S:1197 E:1209 ||| JJ
signaling ||| S:1209 E:1218 ||| NN
.  ||| S:1218 E:1220 ||| .
An  ||| S:1220 E:1223 ||| DT
additional  ||| S:1223 E:1234 ||| JJ
role  ||| S:1234 E:1239 ||| NN
of  ||| S:1239 E:1242 ||| IN
the  ||| S:1242 E:1246 ||| DT
inner  ||| S:1246 E:1252 ||| JJ
medullary  ||| S:1252 E:1262 ||| JJ
interstitial  ||| S:1262 E:1275 ||| JJ
cells  ||| S:1275 E:1281 ||| NNS
and  ||| S:1281 E:1285 ||| CC
PGE-2  ||| S:1285 E:1291 ||| CD
pathway  ||| S:1291 E:1299 ||| NN
has  ||| S:1299 E:1303 ||| VBZ
to  ||| S:1303 E:1306 ||| TO
be  ||| S:1306 E:1309 ||| VB
considered ||| S:1309 E:1319 ||| VBN
.  ||| S:1319 E:1321 ||| .
The  ||| S:1321 E:1325 ||| DT
GSK3ß  ||| S:1325 E:1331 ||| JJ
cascade  ||| S:1331 E:1339 ||| NN
is  ||| S:1339 E:1342 ||| VBZ
also  ||| S:1342 E:1347 ||| RB
regulated  ||| S:1347 E:1357 ||| VBN
by  ||| S:1357 E:1360 ||| IN
Li+ ||| S:1360 E:1363 ||| CD
.  ||| S:1363 E:1365 ||| .
GSK3ß  ||| S:1365 E:1371 ||| NNP
inhibition  ||| S:1371 E:1382 ||| NN
could  ||| S:1382 E:1388 ||| MD
lead  ||| S:1388 E:1393 ||| VB
not  ||| S:1393 E:1397 ||| RB
only  ||| S:1397 E:1402 ||| RB
to  ||| S:1402 E:1405 ||| TO
the  ||| S:1405 E:1409 ||| DT
polyuria ||| S:1409 E:1417 ||| NN
,  ||| S:1417 E:1419 ||| ,
but  ||| S:1419 E:1423 ||| CC
also  ||| S:1423 E:1428 ||| RB
to  ||| S:1428 E:1431 ||| TO
the  ||| S:1431 E:1435 ||| DT
Li+-dependent  ||| S:1435 E:1449 ||| JJ
proliferative  ||| S:1449 E:1463 ||| JJ
effect  ||| S:1463 E:1470 ||| NN
on  ||| S:1470 E:1473 ||| IN
principal  ||| S:1473 E:1483 ||| JJ
cells ||| S:1483 E:1488 ||| NNS
.  ||| S:1488 E:1490 ||| .
Cellular  ||| S:1490 E:1499 ||| JJ
reorganization  ||| S:1499 E:1514 ||| NN
of  ||| S:1514 E:1517 ||| IN
the  ||| S:1517 E:1521 ||| DT
collecting  ||| S:1521 E:1532 ||| JJ
duct  ||| S:1532 E:1537 ||| NN
and  ||| S:1537 E:1541 ||| CC
microcysts  ||| S:1541 E:1552 ||| NNS
are  ||| S:1552 E:1556 ||| VBP
the  ||| S:1556 E:1560 ||| DT
main  ||| S:1560 E:1565 ||| JJ
pathological  ||| S:1565 E:1578 ||| JJ
findings  ||| S:1578 E:1587 ||| NNS
during  ||| S:1587 E:1594 ||| IN
Li+  ||| S:1594 E:1598 ||| CD
treatment ||| S:1598 E:1607 ||| NN
.  ||| S:1607 E:1609 ||| .
Their  ||| S:1609 E:1615 ||| PRP$
relationship  ||| S:1615 E:1628 ||| NN
with  ||| S:1628 E:1633 ||| IN
the  ||| S:1633 E:1637 ||| DT
urinary  ||| S:1637 E:1645 ||| JJ
concentration  ||| S:1645 E:1659 ||| NN
defect  ||| S:1659 E:1666 ||| NN
and  ||| S:1666 E:1670 ||| CC
an  ||| S:1670 E:1673 ||| DT
eventual  ||| S:1673 E:1682 ||| JJ
Li+-induced  ||| S:1682 E:1694 ||| CD
ciliopathy  ||| S:1694 E:1705 ||| NN
has  ||| S:1705 E:1709 ||| VBZ
to  ||| S:1709 E:1712 ||| TO
been  ||| S:1712 E:1717 ||| VBN
investigated ||| S:1717 E:1729 ||| VBN
.  ||| S:1729 E:1731 ||| .
Li+-induced  ||| S:1731 E:1743 ||| NNP
NDI  ||| S:1743 E:1747 ||| NNP
has  ||| S:1747 E:1751 ||| VBZ
been  ||| S:1751 E:1756 ||| VBN
a  ||| S:1756 E:1758 ||| DT
matter  ||| S:1758 E:1765 ||| NN
of  ||| S:1765 E:1768 ||| IN
investigation  ||| S:1768 E:1782 ||| NN
since  ||| S:1782 E:1788 ||| IN
the  ||| S:1788 E:1792 ||| DT
early  ||| S:1792 E:1798 ||| JJ
1970s ||| S:1798 E:1803 ||| NNS
.  ||| S:1803 E:1805 ||| .
This  ||| S:1805 E:1810 ||| DT
manuscript  ||| S:1810 E:1821 ||| NN
reports  ||| S:1821 E:1829 ||| VBZ
the  ||| S:1829 E:1833 ||| DT
latest  ||| S:1833 E:1840 ||| JJS
clinical  ||| S:1840 E:1849 ||| JJ
and  ||| S:1849 E:1853 ||| CC
experimental  ||| S:1853 E:1866 ||| JJ
findings  ||| S:1866 E:1875 ||| NNS
in  ||| S:1875 E:1878 ||| IN
combination  ||| S:1878 E:1890 ||| NN
with  ||| S:1890 E:1895 ||| IN
the  ||| S:1895 E:1899 ||| DT
older  ||| S:1899 E:1905 ||| JJR
fundamental  ||| S:1905 E:1917 ||| JJ
results ||| S:1917 E:1924 ||| NNS
.  ||| S:1924 E:1926 ||| .
